Abstract

BackgroundHuman monocyte-derived DC (mDC) loaded with peptides, protein, tumor cell lysates, or tumor cell RNA, are being tested as vaccines against multiple human malignancies and viral infection with great promise. One of the factors that has limited more widespread use of these vaccines is the need to generate mDC in large scale. Current methods for the large-scale cultivation of mDC in static culture vessels are labor- and time- intensive, and also require many culture vessels. Here, we describe a new method for the large-scale generation of human mDC from human PBMC from leukopheresis or buffy coat products using roller bottles, never attempted before for mDC generation. We have tested this technology using 850 cm2 roller bottles compared to conventional T-175 flat-bottom static culture flasks.MethodsDC were generated from adherent human PBMC from buffy coats or leukopherisis products using GM-CSF and IL-4 in T-175 static flasks or 850 cm2 roller bottles. The cells were matured over two days, harvested and analyzed for cell yield and mature DC phenotype by flow cytometry, and then functionally analyzed for their ability to activate allogeneic T-cell or recall antigen peptide-specific T-cell responses.ResultsMonocytes were found to adhere inside roller bottles to the same extent as in static culture flasks. The phenotype and function of the mDC harvested after maturation from both type of culture systems were similar. The yield of mDC from input PBMC in the roller bottle system was similar as in the static flask system. However, each 850 cm2 roller bottle could be seeded with 4–5 times more input PBMC and could yield 4–5 times as many mDC per culture vessel than the static flasks as a result.ConclusionOur results indicate that the roller bottle technology can generate similar numbers of mDC from adherent PBMC as traditional static flask methods, but with having to use fewer culture vessels. Thus, this may be a more practical method to generate mDC in large-scale cutting down on the amount of laboratory manipulations, and can save both time and labor costs.

Highlights

  • Human monocyte-derived Dendritic cells (DC) loaded with peptides, protein, tumor cell lysates, or tumor cell RNA, are being tested as vaccines against multiple human malignancies and viral infection with great promise

  • peripheral blood mononuclear cell (PBMC) from normal donor buffy coats were seeded into 490 cm2 roller bottles or T-175 culture flasks and adhered for 2.5 h (1 rpm for the roller bottles) in the incubator

  • PBMC from a normal donor leukopheresis product was seeded into 850 cm2 roller bottles or into T-175 flasks and the monocytes adhered for 2.5 h as described in the Methods section

Read more

Summary

Introduction

Human monocyte-derived DC (mDC) loaded with peptides, protein, tumor cell lysates, or tumor cell RNA, are being tested as vaccines against multiple human malignancies and viral infection with great promise. We describe a new method for the large-scale generation of human mDC from human PBMC from leukopheresis or buffy coat products using roller bottles, never attempted before for mDC generation We have tested this technology using 850 cm roller bottles compared to conventional T-175 flat-bottom static culture flasks. This powerful ability of DC is being tested as an active vaccine approach to treat cancer and viral infections such as HIV and CMV [2,3] Most of these studies use monocyte-derived DC (mDC) loaded with antigen in vitro and injected subcutaneously or intravenously [4]. Any improvements in the speed and ease of generating DC from adherent monocytes in large scale and better purity for clinical use would be a great asset

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call